依赖于端粒延长替代机制的胶质瘤临床前模型及应用现状
The Preclinical Models of Glioma Dependent on Alternative Lenthening of Telomeres(ALT)and Current Applications
仝津恺 1闫思翔 1张艳多 1侯凯龙 1张科 1张昊楠 1常顺 2贾舒婷1
作者信息
- 1. 昆明理工大学医学院衰老与肿瘤分子遗传学实验室,昆明 650500
- 2. 云南省第一人民医院神经外科,昆明 650032
- 折叠
摘要
胶质瘤是中枢神经系统最常见的恶性肿瘤,主要起源于神经胶质细胞.由于胶质瘤具有高度侵袭性的特点,其死亡率在各种癌症中名列前茅.因此,新的治疗方法和新的药物开发对于胶质瘤的治疗意义十分重大.在大约30％的胶质瘤中,端粒的维持并不是通过端粒酶的激活延长的,而是通过端粒延长替代机制(ALT)来维持和延长端粒.然而,由于目前对于ALT胶质瘤细胞系以及临床前的ALT胶质瘤模型的研究还比较匮乏,从而制约了ALT胶质瘤的机制研究.因此,本篇综述在此探讨了目前发现的ALT胶质瘤细胞系及ALT胶质瘤动物模型,以及这些模型在临床前研究中发挥的作用和最新的进展.
Abstract
Glioma is the most common malignancy of the central nervous system,originating mainly from glial cells.Because of its highly aggressive nature,glioma has one of the highest rates of death among all types of cancer.Therefore,it is very important to develop new therapeutic approaches and drugs for glioma treatment.Instead of activate the telomerase,approximately 30％of glioma use alternative lenthening of telomere(ALT)to maintain telomere length.The mechanism of ALT development is poorly understood,however,some genetic mutations have been reported to induce the development of ALT glioma,such as ATRX,IDH1,p53,etc.The lack of ALT glioma cell lines and preclinical ALT glioma models has limited the mechanistic studies of ALT glioma.Therefore,this review listed ALT glioma cell lines that derived from primary culture or gene editing in the last decade,as well as the xenografted animal models established by ALT glioma cell lines,and discussed the role and significance these cell and animal models play in preclinical studies.
关键词
胶质瘤/端粒延长替代机制/临床前模型Key words
glioma/alternative lenthening of telomere/preclinical model引用本文复制引用
基金项目
云南省科技厅科技计划(202101AY070001-235)
云南省科技厅科技计划(202201AS070074)
云南省"兴滇英才"(YN-WRQNBJ-2019-240)
出版年
2024
NETL
NSTL
万方数据